---

Bio:

Present Role:

• Founder and CEO of Specimen Bio, Peter is an experienced leader manager with over 25 years of professional experience in various roles including as Manager, Director, Managing Director, Vice President, COO, General Manager, Management Consultant, Executive Advisor.
• In addition to leading Specimen Bio, Peter volunteers and mentors start-up founders.

Prior Roles Included:

• Management Consultant, Mentor, Advisor
• Senior Director and General Manager, Biospecimen Procurement Business Unit, Azenta Life Sciences (formerly Brooks Life Sciences),
• Senior Director and General Manager, Biological Logistics Business Unit, Azenta Life Sciences (formerly Brooks Life Sciences)
• COO and Advisor to CEO for Strategy and Corporate Development, Trans-Hit Biomarkers (sold to Brooks Life Sciences)
• Director of International Business Development, Medicover Diagnostic Services (Synevo), Berlin, Germany
• Director of New Business Development, Medicover Healthcare Services, Warsaw, Poland
• Vice-President Healthcare and Board Director and Chief Operating Officer, Diagnos, Montréal, Canada and Mumbai, India
• Director of Metrics and Reporting, Inforoute Santé du Canada, Montréal, Canada
• Director of Information Technology & Bioinformatics, Ecopia Biosciences, Montréal, Canada
• Subject Matter Expert & Consultant, Genomic Diseases Research Centre, Melbourne, Australia
• Coordinator, Bioinformatics, Montreal General Hospital Research Institute, Montréal, Canada
• Project Manager IT, Montreal Children’s Hospital Research Institute, Montréal, Canada
• Bioinformatics SME, Phenylalanine Hydroxylase Consortium, Montréal, Canada

---

Education

• MBA, Queen’s University, Kingston, Canada
• MSc, Biology & Informatics, (Dean’s Honor List), McGill University, Montréal, Canada
• BSc, Honors Biology, Concordia University, Montréal, Canada

---

Publications

• 18) Tumilasci V., Nowacki P.M., Puchois P. The Promise and Plight of BioBanking Initiatives During the COVID-19 Pandemic: The Urgent Need to Change Existing Practices. Trans-Hit Bio White Paper.
• 17) Scriver C.R., Nowacki P.M., and Lehvaslaiho H. Guidelines and Recommendations for Content, Structure, and Deployment of Mutation Databases: Journey in progress. Hum Mutat, 2000;15(1):13-5, PMID: 10612816.
• 16) Scriver CR, Waters PJ, Sarkissian C, Ryan S, Prevost L, Cote D, Novak J, Teebi S, Nowacki P.M. PAHdb: a locus-specific knowledgebase. Human Mutation 2000;15(1):99-104. PMID: 10612829.
• 15) Scriver C.R., Nowacki P.M. Genomics, Mutations and the Internet: the naming and use of parts. J Inherit Metab Dis. 1999 Jun;22(4):519-30. PMID: 10407783.
• 14) Scriver C.R., Nowacki P.M., Cotton R.G. The HUGO Mutation Database Initiative. Genome Digest. Jun 1998.
• 13) Scriver CR, Nowacki P.M., Lehvaslaiho H. Guidelines and recommendations for content, structure, and deployment of mutation databases. Hum Mutat. 1999;13(5):344-50. PMID: 10338088.
• 12) Nowacki P.M., Byck S., Prevost L. and Scriver C.R. (curators) PAH Mutation Analysis Consortium Database: 1997 Prototype for Relational Locus-Specific Mutation Databases. Nucleic Acids Research Jan 1;26(1):220-225, 1998.
• 11) Carter K., Byck S., Waters P.J., Richards B., Nowacki P.M., Laframboise R., Lambert M., Treacy E., Scriver C.R. Mutation at the Phenylalanine Hydroxylase Gene (PAH) and Its Use to Document Population Genetic Variation: The Quebec Experience. European Journal of Human Genetics, 6: 61-70, 1998.
• 10) Waters P.J., Parniak M.A., Nowacki P., Scriver C.R. In Vitro Expression Analysis of mutations in Human and Rat Phenylalanine Hydroxylase: Exploring Molecualr Causes of Hyperphenylalaninemia. Hum Mutat, 11(1):4-17, 1998.
• 9) Kayaalp E., Treacy E., Waters P.J., Byck S., Nowacki P.M., Scriver C.R. Human PAH Mutations and Hyperphenylalaninemia Phenotypes: A Meta-Analysis of Genotype-Phenotype Correlations. Am J Hum Genet Dec;61(6):1309-1317, 1997.
• 8) Nowacki P.M., Byck S., Prevost L., Scriver C.R. The PAH Mutation Analysis Consortium Database Update 1996. Nucleic Acids Research, 1997, vol. 25, no.1:139-142.
• 7) Nowacki P.M., Scriver C.R., Discussion Paper of the Mutation Database Meeting (HUGO Europe), 29 October, 1996. San Francisco. (Reviewed by Prof R.G.H. Cotton, Editor)
• 6) http://ariel.ucs.unimelb.edu.au:80~cotton/proposals.htm
• 5) Byck S., Hoang L., Nowacki P.M., Prevost L., Scriver C., PAH Consortium Newsletter. PAH Mutation Analysis Consortium publication. Spring 1996 edition. Apr. 1996.
• 4) Scriver C., Nowacki P.M., Byck S., Prevost L., GenBank Submission U49897. NCBI GenBank Mar 96.
• 3) Jothy S., Flanders T.Y., Nowacki P.M. New Developments in the Molecular Pathology of Human Colon Cancer: Relevance to Pathogenesis and Diagnosis. Advances in Anatomic Pathology. 1996, Vol.3., No.6:343-350.
• 2) Nowacki M.P., Janik P., Nowacki P.M., Inflammation and Metastases. Medical Hypothesis. Medical Hypotheses. 1996, Vol.47:193-196.
• 1) Nowacki P.M., Jothy S., Recent Advances in the Molecular Biology of Colon Cancer: the Clinical and Pathological Significance. Gastroenterologia Polska 1995, 2, 4.